Treating bipolar disorder - Evidence-based guidelines for family medicine

被引:0
|
作者
McIntyre, RS
Mancini, DA
Lin, P
Jordan, J
机构
[1] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[2] Univ Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
[3] Univ Toronto, Hlth & Wellness Ctr, Scarborough Clin, Toronto, ON, Canada
[4] Univ Western Ontario, Dept Family Med, London, ON, Canada
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE To provide an evidence-based summary of medications commonly used for bipolar disorders and a practical approach to managing bipolar disorders in the office. QUALITY OF EVIDENCE Articles from 1990 to 2003 were selected from MEDLINE using the key words "bipolar disorder," "antiepileptics," "antipsychotics," "antidepressants," and "mood stabilizers." Good-quality evidence for many of these treatments comes from randomized trials. Lithium, divalproex, carbamazepine, lamotrigine, oxcarbazepine, and some novel antipsychotics all have level I evidence for treating various aspects of the disorder. MAIN MESSAGE Treatment of bipolar disorder involves three therapeutic domains: acute mania, acute depression, and maintenance. Lithium has been a mainstay of treatment for some time, but antiepileptic drugs like divalproex, carbamazepine, and lamotrigine, along with novel antipsychotic drugs like olanzapine, risperidone, and quetiapine, alone or in combination, are increasingly being used successfully to treat acute mania and to maintain mood stability. CONCLUSION Bipolar disorder is more common in family practice than previously believed. Drug treatments for this complex disorder have evolved rapidly over the past decade, radically changing its management. Treatment now tends to be very successful.
引用
收藏
页码:388 / 394
页数:7
相关论文
共 50 条
  • [1] CINP evidence-based guidelines for bipolar disorder
    Yatham, L.
    Milev, R.
    Vieta, E.
    Young, A.
    Schaffer, A.
    [J]. BIPOLAR DISORDERS, 2017, 19 : 18 - 18
  • [2] Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology
    Goodwin, GM
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (02) : 149 - 173
  • [3] Myth of evidence-based medicine for bipolar disorder
    Post, Robert M.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (09) : 1271 - 1273
  • [4] Evidence-based medicine and evidence-based guidelines
    Sekimoto, Miho
    Imanaka, Yuichi
    [J]. PANCREAS, 2007, 35 (01) : 87 - 88
  • [5] An evidence-based medicine strategy for achieving remission in bipolar disorder
    Beyer, John L.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 : 31 - 37
  • [6] Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
    Goodwin, G. M.
    Haddad, P. M.
    Ferrier, I. N.
    Aronson, J. K.
    Barnes, T. R. H.
    Cipriani, A.
    Coghill, D. R.
    Fazel, S.
    Geddes, J. R.
    Grunze, H.
    Holmes, E. A.
    Howes, O.
    Hudson, S.
    Hunt, N.
    Jones, I.
    Macmillan, I. C.
    McAllister-Williams, H.
    Miklowitz, D. R.
    Morriss, R.
    Munafo, M.
    Paton, C.
    Saharkian, B. J.
    Saunders, K. E. A.
    Sinclair, J. M. A.
    Taylor, D.
    Vieta, E.
    Young, A. H.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (06) : 495 - 553
  • [7] Is there consensus across international evidence-based guidelines for the management of bipolar disorder?
    Parker, G. B.
    Graham, R. K.
    Tavella, G.
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2017, 135 (06) : 515 - 526
  • [8] Guidelines and evidence-based Medicine
    Esser, E.
    Ulrich, H. -P.
    [J]. MKG-CHIRURG, 2009, 2 (02): : 69 - 70
  • [9] Evidence-based medicine and guidelines
    Hollingworth, B
    [J]. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2004, 30 (04): : 276 - 276
  • [10] Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology
    Goodwin, G. M.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2009, 23 (04) : 346 - 388